Canada· CA-DIN-02506343
GIVLAARI
A givosiran product containing givosiran (givosiran sodium), registered in Canada by ALNYLAM NETHERLANDS B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Givosiran is registered in 13 of 19 countries.
Countries holding a registration under ATC A16AX16 (givosiran), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Givosiran · ATC A16AX16
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- GIVOSIRAN (GIVOSIRAN SODIUM)
- Manufacturer
- ALNYLAM NETHERLANDS B.V.
- Country
- Canada (CA)
- ATC code
- A16AX16
- ATC class
- Givosiran
- Defined daily dose
- 5.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
105 interactions on record for givosiran.
Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Givosiran · interactions on record
105 records
- 24 severe
- 81 moderate
Most severe, free to view
- EliglustatA16AX10severe
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Givosiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandGivlaari
- SpainGIVLAARI 189 MG/ML SOLUCION INYECTABLEAlnylam Netherlands B.V.
- FranceGIVLAARI 189 mg/mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- United KingdomGivlaari 189mg/1ml solution for injection vialsAlnylam UK Ltd
- IcelandGivlaariAlnylam Netherlands B.V.
- NetherlandsGivlaari 189 mg/ml oplossing voor injectieAlnylam Netherlands B.V.
- PolandGivlaariAlnylam Netherlands B.V.
- SwedenGivlaari 189 mg/ml Injektionsvätska, lösningAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Givlaari
- Liechtenstein · Givlaari
- Norway · Givlaari
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2c91031a-b205-47e7-9b33-0e85b8bdb896 GET /v1/drugs/2c91031a-b205-47e7-9b33-0e85b8bdb896?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02506343",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A16AX16",
"schedule": [
"Prescription"
],
"drug_code": "99566",
"strengths": [
"189 MG"
],
"ahfs_class": null,
"substances": [
"GIVOSIRAN (GIVOSIRAN SODIUM)"
],
"product_categorization": null
}See everything about givosiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.